Publications

2018

Virnik K, Nesti E, Dail C, Scanlan A, Medvedev A, Vassell R, McGuire AT, Stamatatos L, Berkower I. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost. [SEL1] Vaccine. 2018 Aug 16;36(34):5166-5172

Yacoob C, Lange MD, Cohen K, Lathia K, Feng J, Glenn J, Carbonetti S, Oliver B, Vigdorovich V, Sather DN, Stamatatos L. B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques. PLoS Pathog. 14(6):e1007120, 2018

Dosenovic P, Kara EE, Pettersson AK, McGuire AT, Gray M, Hartweger H, Thientosapol ES, Stamatatos L, Nussenzweig MC. Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. Proc Natl Acad Sci USA. 115(18): 4743-4748, 2018

Bonsignori M, Scott E, Wiehe K, Easterhoff D, Alam SM, Hwang KK, Cooper M, Xia SM, Zhang R, Montefiori DC, Henderson R, Nie X, Kelsoe G, Moody MA, Chen X, Joyce MG, Kwong PD, Connors M, Mascola JR, McGuire AT, Stamatatos L, Medina-Ramirez M, Sanders RW, Saunders KO, Kepler TB, Hanyes BF. Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. Immunity. 2018 Dec 18;49(6): 1162-1174

Borst AJ, Weidle CE, Gray MD, Frenz B, Snijder J, Joyce MG, Georgiev IS, Stewart-Jones GB, Kwong PD, McGuire AT, Dimaio F, Stamatatos L, Pancera M, Veesler D. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. Elife. 2018 Nov 7;7. pii: e37688. doi: 10.7554/eLife.37688

LaBranche CC, McGuire AT, Gray MD, Behrens S, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Saunders KO, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC. HIV-1 envelope glycan modifications that permit neautralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathog. 2018 Nov 5;14(11):e1007431. doi: 10.1371/journal.ppat.1007431

2017

Avnir Y, Prachanronarong KL, Zhang Z, Hou S, Peterson EC, Sui J, Zayed H, Kurella VB, McGuire AT, Stamatatos L, Hilbert BJ, Bohn MF, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Goodall M, Jefferis R, Zhu Q, Kurt Yilmaz N, Schiffer CA, Marasco WA. Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope. Cell Rep. 21(11): 3243-3255, 2017.

Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof TLGM, Freund NT, Dosenovic P, Hua Y, Gitlin AD, Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med. 214(9): 2573-2590, 2017.

Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, Chambers M, Druz A, Geng H, McKee K, Kwon YD, O'Dell S, Sastry M, Schmidt SD, Xu K, Chen L, Chen RE, Louder MK, Pancera M, Wanninger TG, Zhang B, Zheng A, Farney SK, Foulds KE, Georgiev IS, Joyce MG, Lemmin T, Narpala S, Rawi R, Soto C, Todd JP, Shen CH, Tsybovsky Y, Yang Y, Zhao P, Haynes BF, Stamatatos L, Tiemeyer M, Wells L, Scorpio DG, Shapiro L, McDermott AB, Mascola JR, Kwong PD. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Rep. 19(4): 719-732, 2017.

Stamatatos L, Pancera M, McGuire AT. Germline-targeting immunogens. Immunol. 275(1):203-216, 2017.

2016

Yacoob, C., Pancera, M., Vigdorovich, V., Oliver, B.G., Glenn, J. A., Feng, J., Sather, D.N., McGuire, AT, Stamatatos, L. Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. Cell Rep. 17(6): 1560-1570, 2016.

Vigdorovich, V., Oliver, B. G., Carbonetti, S., Dambrauskas, N., Lange, M. D., Yacoob, C., Leahy, W., Callahan, J., Stamatatos, L., Sather, D.N. Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing. Clin Transl Immunology. 5(7): e93, 2016.

Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. J Immunol. 196(7):3064-78, 2016. 

Scharf L, West AP, Sievers SA, Chen C, Jiang S, Gao H, Gray MD, McGuire AT, Scheid JF, Nussenzweig MC, Stamatatos L, Bjorkman PJ. Structural basis for germline antibody recognition of HIV-1 immunogens. Elife. 5:e13783, 2016 

McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, Stamatatos L. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun. 7(10618), 2016. 

2015

Dosenovic, P., L. von Boehmer, A. Escolano, J. Jardine, N.T. Freund, A.D. Gitlin, A.T. McGuire, D.W. Kulp, T. Oliveira, L. Scharf, J. Pietzsch, M.D. Gray, A. Cupo, M.J. van Gils, K.H. Yao, C. Liu, A. Gazumyan, M.S. Seaman, P.J. Bjorkman, R.W. Sanders, J.P. Moore, L. Stamatatos, W.R. Schief, M.C. Nussenzweig. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 161(7):1505-15,  2015.

Zhou, T., R.M. Lynch, L. Chen, P. Acharya, X. Wu, N.A. Doria-Rose, M.G. Joyce, D. Lingwood, C. Soto, R.T. Bailer, M.J. Ernandes, R. Kong, N.S. Longo, M.K. Louder, K. McKee, S. O'Dell, S.D. Schmidt, L. Tran, Z. Yang, A. Druz, T.S. Luongo, S. Moquin, S. Srivatsan, Y. Yang, B. Zhang, A. Zhang, M. Pancera, T. Kirys, I.S. Georgiev, T. Gindin, H.P. Peng, A.S. Yang; NISC Comparative Sequencing Program, J.C. Mullikin, M.D. Gray, L. Stamatatos, D.R. Barton, W.C. Koff, M.S. Cohen, B.F. Haynes, J.P. Casazza, M. Connors, D. Corti, A. Lanzavecchia, Q.J. Sattentau, R.A. Weiss, A.P. West Jr, P.J. Bjorkman, J.F. Scheid, M.C. Nussezweig, L. Shapiro, J.R. Mascola, P.D. Kwong. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell. 161(6):1280-92, 2015. 

Cohen, K.W., A-S. Dugast, G. Alter, M.J. McElrath and L. Stamatatos. HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN. J. Immunol. 194(6):2769-75, 2015.

Bricault, C., J. Kovacs, J. Nkolola, K. Yusim, E. Giorgi, J. Shields, J. Perry, C. Lavine, A. Cheung, K. Ellingson-Strouss, C. Rademeyer, G. Gray, C. Williamson, L. Stamatatos, M. Seaman, B. Korber, B. Chen, and D. Barouch. A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. J. Virol. 89(5):2507-19, 2015.

Chang, H. W., L. Tartaglia, J. Whitney, S.Y. Lim, S. Sanisetty, C. Lavine, M. Seaman, C. Rademeyer, C. Williamson, K. Ellingson-Strouss, L. Stamatatos, J. Kublin, and D. Barouch. Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks. J. Virol. 89(4):1965-74, 2015.

2014

McGuire, M.T., A.M. Dreyer, S. Carbonetti, A. Lippy, J. Glenn, J.F. Scheid, H. Mouquet, and L. Stamatatos. HIV Antibodies. Antigen-modification regulates competition of broad and narrow neutralizing HIV antibodies. Science. 346(6215):1380-83, 2014.

Cohen, K., M. Altfeld, G. Alter and L. Stamatatos. Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J. Virol. 88(22):13310-21, 2014.

Sather, D.N., S. Carbonetti, D.C. Malherbe, F. Pissani, A.B. Stuart, A.J. Hessell, M.D. Gray, I. Mikell, S.A. Kalams, N.L. Haigwood, and L. Stamatatos. Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1. J. Virol. 88(22):12968-81, 2014.

Dugast, A.S., L. Stamatatos,T.J. Suscovich, A.F. Licht, I. Mikell, M.E. Ackerman, H. Streeck, P.J. Klasse, J.P. Moore, G. Alter. Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity begins during acute infection. Eur J Immunol. 44(10):2925-37, 2014.

Finton, K.A., D. Friend, J. Jaffe, M. Gewe, M.A. Holmes, H.B. Larman, A. Stuart, K. Larimore, P.D. Greenberg, S.J. Elledge, L. Stamatatos and R.K. Strong. Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10. PLoS Pathog. 10(9):e1004403, 2014.

Avnir, Y., A.S. Tallarico, Q. Zhu, A.S. Bennett, G. Connelly, J. Sheehan, J. Sui, A. Fahmy, C.Y. Huang, G. Cadwell, L.A. Bankston, A.T. McGuire, L. Stamatatos, G. Wagner, R.C. Liddington, W.A. Marasco. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog. 10(5):e1004103, 2014.

McGuire, A.T., J.A. Glenn, A. Lippy, L. Stamatatos. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol. 88(5):2645-57, 2014.

Carbonetti, S., B.G. Oliver, J. Glenn, L. Stamatatos, D.N. Sather. Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies. PLoS One. 9(1):e86905, 2014.

2013

Diskin R, Klein F, Horwitz JA, Halper-Stromberg A, Sather DN, Marcovecchio PM, Lee T, West AP Jr, Gao H, Seaman MS, Stamatatos L, Nussenzweig MC, Bjorkman PJ. Restricting HIV Pathways for Escape using Rationally-Designed Anti-HIV Antibodies. J Exp Med. 210(6):1235-49, 2013

Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR. Rational HIV immunogen design to target specific germline B cell receptors. Science. 340(6133):711-6, 2013.

McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp Med. 210(4):655-63, 2013.

Hoot S, McGuire AT, Choen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 9(1):e1003106, 2013.

2012

Sather DN, Carbonetti S, Kehayia J, Kraft Z, Mikell I, Scheid JF, Klein F, Stamatatos L. Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost to the contemporaneous virus. J Virol. 86(23):12676-85, 2012.

Mikell, I., and L. Stamatatos. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. PLoS One. 7(11):e49610, 2012

Pissani F, Malherbe DC, Robins H, DeFilippis VR, Park B, Sellhorn G, Stamatatos L, Overbaugh J, Haigwood NL. Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine. 30(37):5519-26, 2012.

McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, Mittler JE, Kraft Z, Stamatatos L, Horton H, De Rosa SC, Coombs RW, Polyak SJ. Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation. PLoS One. 7(7):e41832, 2012.

Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fatkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med. 209(8):1469-79, 2012.

L. Stamatatos. HIV Vaccine design: The neutralizing antibody conundrum. Curr Opin Immunol. 24(3):316-23, 2012.

Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L. Engineering, expression, purification and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. J Virol. 86(1):128-42, 2012.

Selected publications prior to 2012

Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, and Stamatatos L. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1. PLoS Pathog. 7(1):e1001251, 2011.

Correia BE, Ban YE, Friend DJ, Ellingson K, Xu H, Boni E, Bradley-Hewitt T, Bruhn-Johannsen JF, Samatatos L, Strong RK, Schief WR. Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. J Mol Biol. 405(1):284-97, 2011.

Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, Kraft Z, Carrico C, Boni E, Sather DN, Zenobia C, Burke KY, Bradley-Hewitt T, Bruhn-Johannsen JF, Kalyuzhniy O, Baker D, Strong RK, Stamatatos L, Schief WR. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure. 18(9):1116-26, 2010.

Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med. 15(8):866-70, 2009.

Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol. 83(2):757-69, 2009.

Kraft Z, Derby NR, McCaffrey RA, Niec R, Blay WM, Haigwood NL, Moysi E, Saunders CJ, Wrin T, Petropoulos CJ, McElrath MJ, Stamatatos L. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol. 81(12):6402-11, 2007.

Cherpelis S, Shrivastava I, Getie A, Jin X, Ho DD, Barnett SW, Stamatatos L. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J Virol. 75(3):1547-50, 2001.

Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol. 75(12):5526-40, 2001.

Ly, A, Stamatatos, L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates the interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol. 74(15):6769-6776, 2000.

Ignatius R, Mahnke K, Rivera M, Hong K, Isdell F, Steinman RM, Pope M, Stamatatos L. Presentation of proteins encapsulated into sterically stabilized liposomes by dendritic cells initiates CD8 (+) T-cell responses in vivo. Blood. 96(10):3505-13, 2000.